Neurogene Inc.

NGNE

US64135M1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 21/01/2026 GMT			5-day change	1st Jan Change
18.31 ^USD	+4.51%		-2.61%	-11.12%

01-12	Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-In-Class Gene Therapy for Rett Syndrome	CI
11-13	Gene therapy developer Neurogene's Q3 net loss widens	RE

Neurogene Inc.(NasdaqGM:NGNE) dropped from Russell Small Cap Comp Growth Index

Published on 06/30/2025 at 04:25 am BST

S&P Capital IQ

NEUROGENE INC.

+4.51%

Neurogene Inc.(NasdaqGM:NGNE) dropped from Russell Small Cap Comp Growth Index

Latest news about Neurogene Inc.

01-12	Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-In-Class Gene Therapy for Rett Syndrome	CI
11-13	Gene therapy developer Neurogene's Q3 net loss widens	RE
11-13	Neurogene Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-13	Neurogene Inc. Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome Multidomain	CI
11-12	Neurogene Inc. Presents at Stifel 2025 Healthcare Conference, Nov-12-2025 04:40 PM
11-06	Neurogene Doses First Patient in Registrational Trial of NGN-401 for Rett Syndrome	MT
11-06	Neurogene Inc. Announces First Participant Dosed in Embolden?? Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome	CI
09/10/25	Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Fourth Quarter of 2025	CI
09/10/25	Neurogene Shares Rise After NGN-401 Discussions With FDA	DJ
09/10/25	Neurogene Plans to Initiate Dosing in Registrational Trial in Q4 2025	MT
03/10/25	Neurogene announces inducement grants under Nasdaq Listing Rule	RE
05/09/25	Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
11/08/25	Neurogene Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
08/08/25	Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
30/06/25	Neurogene Inc. Announces Registrational Trial Design for Embolden? Study of NGN-401 Gene Therapy for Rett Syndrome	CI
30/06/25	Neurogene Inc.(NasdaqGM:NGNE) dropped from Russell Microcap Growth Index	CI
30/06/25	Neurogene Inc.(NasdaqGM:NGNE) dropped from Russell 3000E Growth Index	CI
30/06/25	Neurogene Inc.(NasdaqGM:NGNE) dropped from Russell 2500 Growth Index	CI
30/06/25	Neurogene Inc.(NasdaqGM:NGNE) dropped from Russell 2000 Growth Index	CI
30/06/25	Neurogene Inc.(NasdaqGM:NGNE) dropped from Russell 3000 Growth Index	CI
30/06/25	Neurogene Inc.(NasdaqGM:NGNE) dropped from Russell Small Cap Comp Growth Index	CI
29/06/25	Neurogene Inc.(NasdaqGM:NGNE) dropped from Russell Small Cap Comp Growth Benchmark	CI
29/06/25	Neurogene Inc.(NasdaqGM:NGNE) dropped from Russell 3000E Growth Benchmark	CI
29/06/25	Neurogene Inc.(NasdaqGM:NGNE) dropped from Russell 3000 Growth Benchmark	CI
29/06/25	Neurogene Inc.(NasdaqGM:NGNE) dropped from Russell 2500 Growth Benchmark	CI

Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is under development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in pediatric female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.

Employees

107

Sector

Biotechnology & Medical Research

Calendar

03-22 - Q4 2025 Earnings Release (Projected)

More about the company